KR20200052936A - 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민 - Google Patents

과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민 Download PDF

Info

Publication number
KR20200052936A
KR20200052936A KR1020207010465A KR20207010465A KR20200052936A KR 20200052936 A KR20200052936 A KR 20200052936A KR 1020207010465 A KR1020207010465 A KR 1020207010465A KR 20207010465 A KR20207010465 A KR 20207010465A KR 20200052936 A KR20200052936 A KR 20200052936A
Authority
KR
South Korea
Prior art keywords
compound
mmol
hyperglycemia
optionally substituted
mixture
Prior art date
Application number
KR1020207010465A
Other languages
English (en)
Korean (ko)
Inventor
벤자민 펠크만
토레 벵트손
Original Assignee
아트로기 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트로기 에이비 filed Critical 아트로기 에이비
Priority to KR1020237043200A priority Critical patent/KR20230175328A/ko
Publication of KR20200052936A publication Critical patent/KR20200052936A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • C07D213/6432-Phenoxypyridines; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020207010465A 2017-09-13 2018-09-13 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민 KR20200052936A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043200A KR20230175328A (ko) 2017-09-13 2018-09-13 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1714745.5A GB201714745D0 (en) 2017-09-13 2017-09-13 New compounds and uses
GB1714745.5 2017-09-13
PCT/GB2018/052595 WO2019053427A1 (en) 2017-09-13 2018-09-13 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINO FOR USE IN THE TREATMENT OF HYPERGLYCEMIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043200A Division KR20230175328A (ko) 2017-09-13 2018-09-13 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민

Publications (1)

Publication Number Publication Date
KR20200052936A true KR20200052936A (ko) 2020-05-15

Family

ID=60117187

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207010465A KR20200052936A (ko) 2017-09-13 2018-09-13 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민
KR1020237043200A KR20230175328A (ko) 2017-09-13 2018-09-13 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043200A KR20230175328A (ko) 2017-09-13 2018-09-13 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민

Country Status (22)

Country Link
US (2) US11357757B2 (pl)
EP (2) EP3971168A1 (pl)
JP (2) JP7358338B2 (pl)
KR (2) KR20200052936A (pl)
CN (1) CN111315726A (pl)
AU (1) AU2018332501B2 (pl)
BR (1) BR112020005113A2 (pl)
CA (1) CA3075707A1 (pl)
CY (1) CY1125004T1 (pl)
ES (1) ES2902073T3 (pl)
GB (1) GB201714745D0 (pl)
HR (1) HRP20220177T1 (pl)
HU (1) HUE057426T2 (pl)
IL (1) IL273180A (pl)
LT (1) LT3681872T (pl)
MX (2) MX2020002825A (pl)
PL (1) PL3681872T3 (pl)
PT (1) PT3681872T (pl)
RS (1) RS62895B1 (pl)
RU (1) RU2020108523A (pl)
SI (1) SI3681872T1 (pl)
WO (1) WO2019053427A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
JP2022527769A (ja) 2019-03-27 2022-06-06 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
CA3144093A1 (en) * 2019-07-01 2021-01-07 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
JP2023528450A (ja) * 2020-06-04 2023-07-04 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物
GB202015035D0 (en) * 2020-09-23 2020-11-04 Atrogi Ab New compounds and methods
GB202015044D0 (en) * 2020-09-23 2020-11-04 Atrogi Ab New compounds and methods
GB2613616A (en) 2021-12-09 2023-06-14 Atrogi Ab New formulations
WO2024153813A1 (en) 2023-01-20 2024-07-25 Atrogi Ab Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202304652D0 (en) * 2023-03-29 2023-05-10 Atrogi Ab New compounds and medical uses thereof

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE45721C (pl)
DE638650C (de) 1934-06-08 1936-11-20 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 3, 4-Dioxyphenylmonoalkylaminobutanolen-1
US2308232A (en) 1939-01-17 1943-01-12 Scheuing Georg Isopropylaminomethyl-(3, 4-dioxyphenyl) carbinol
US2460144A (en) 1946-04-11 1949-01-25 Sterling Drug Inc Hydroxyphenyl alkanolamines
FR1165845A (fr) 1955-05-28 1958-10-29 Philips Nv Amines secondaires portant des substituants et leur préparation
FR1324914A (fr) 1961-01-11 1963-04-26 Philips Nv Procédé de préparation d'aralkylamines substituées optiquement actives
DE1275069B (de) 1960-02-15 1968-08-14 Boehringer Sohn Ingelheim 1-(3', 5'-Dihydroxyphenyl)-1-hydroxy-2-isopropylaminoalkane und Verfahren zu ihrer Herstellung
NL6401871A (pl) 1964-02-27 1965-08-30
GB1142508A (en) * 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
SE335359B (pl) 1966-10-19 1971-05-24 Draco Ab
AT285583B (de) 1968-10-10 1970-11-10 Chemie Linz Ag Verfahren zur Herstellung von N,N'-bis-[2-(3',4'-Dihydroxyphenyl)-2-hydroxyäthyl]-hexamethylendiamin und seinen Salzen
NO129903B (pl) 1969-04-01 1974-06-10 Sterling Drug Inc
GB1321701A (en) 1969-10-01 1973-06-27 Continental Pharma Amino-alcohols their salts and process for prepairing the same
US3910934A (en) 1970-05-21 1975-10-07 Minnesota Mining & Mfg Process for the preparation of {60 -(hydroxy and alkoxy substituted)phenyl-{60 -(2-piperidinyl)-methanols
GB1298494A (en) 1970-06-17 1972-12-06 Allen & Hanburys Ltd Phenylethanolamine derivatives
DE2157040A1 (de) 1971-11-17 1973-05-24 Thomae Gmbh Dr K Neues verfahren zur herstellung von 4-amino-3,5-dihalogen-phenyl-aethanolaminen
US3801631A (en) 1972-02-16 1974-04-02 Mead Johnson & Co 2'-hydroxy-5'-(1-hydroxy-2-(2-methyl-1-phenyl-2-propylamino)ethyl)meth-anesulfonanilide and its salts
DE2300614A1 (de) 1973-01-08 1974-07-18 Thomae Gmbh Dr K Neue optisch aktive verbindungen
DE2259282A1 (de) 1972-12-04 1974-06-12 Thomae Gmbh Dr K Neue aminoaethanole
US4119710A (en) 1972-12-18 1978-10-10 Boehringer Ingelheim Gmbh Bronchospasmolytic 1-(p-amino-phenyl)-2-amino-ethanols-(1) and salts
NL176168C (nl) 1972-12-18 1985-03-01 Thomae Gmbh Dr K Werkwijze ter bereiding respectievelijk vervaardiging van een farmaceutisch preparaat en werkwijze ter bereiding van daarbij bruikbare nieuwe gesubstitueerde 1-(4-aminofenyl)-2-amino-ethanol-derivaten die, behalve een analgetische, uterusspasmolytische en anti-spastische werking op de dwarsgestreepte spieren, in het bijzonder een betaŸ2-mimetische en/of betaŸ1-blokkerende werking bezitten.
US3985887A (en) 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
US3910933A (en) 1973-10-19 1975-10-07 Smithkline Corp 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols
JPS539227B2 (pl) 1973-12-26 1978-04-04
DE2413102C3 (de) 1974-03-19 1980-09-11 C.H. Boehringer Sohn, 6507 Ingelheim Verfahren zur Herstellung von l-(3,5-Dihydroxyphenyl)-t-hydroxy-2- eckige Klammer auf 1-methyl-2-(4-hydroxyphenyl)- äthyl] -aminoäthan
CA1030146A (en) * 1974-04-18 1978-04-25 American Home Products Corporation Thiophene ethanolamines
DE2548053A1 (de) 1974-10-30 1976-05-06 Scherico Ltd Azazyklische verbindungen
US3952101A (en) 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
CH624395A5 (pl) 1976-01-08 1981-07-31 Ciba Geigy Ag
JPS6048503B2 (ja) 1976-02-27 1985-10-28 興和株式会社 新規な1−フエニル−2−アミノエタノ−ル誘導体
JPS609713B2 (ja) 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
AR214005A1 (es) 1977-05-02 1979-04-11 Pfizer Procedimiento para preparar 2-hidroximetil-3-hidroxi-6-(1-hidroxi-2-t-butilaminoetil)piridina
NZ187066A (en) 1977-05-03 1981-02-11 Hoffmann La Roche 4-(3-substitutedamino-2-hydroxypropoxy)-benzimidazolidin-2-(ones or thiones)
JPS5852640B2 (ja) 1977-06-06 1983-11-24 味の素株式会社 ペルオキシダ−ゼ活性の測定方法
FR2424278A1 (fr) * 1978-04-24 1979-11-23 Parcor Procede de preparation de thieno(2,3-c) et thieno(3,2-c)pyridines
DE2838923A1 (de) 1978-09-07 1980-04-03 Thomae Gmbh Dr K Verwendung von phenylaethanolaminen als antiphlogistica
FR2436779A1 (fr) 1978-09-22 1980-04-18 Pharmindustrie Derives de pyrrolidine-2 methanol utilisables comme medicaments
DE3061334D1 (en) 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
FR2460929A1 (fr) 1979-07-06 1981-01-30 Roussel Uclaf Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant
JPS5655369A (en) * 1979-10-12 1981-05-15 Yoshitomi Pharmaceut Ind Ltd Pyridinemethanol derivative
JPS5655355A (en) 1979-10-15 1981-05-15 Paamakemu Asia:Kk Preparation of alkylenediamine derivative
FR2486074A1 (fr) 1979-12-14 1982-01-08 Lafon Labor Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique
EP0043807B1 (en) 1980-07-09 1984-05-30 Aktiebolaget Draco 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates
JPS57169450A (en) 1981-04-13 1982-10-19 Lafon Labor Fluorophenacyl-amine derivative and application to remedy
PL144053B1 (en) 1983-01-31 1988-04-30 Lilly Co Eli Method of stimulating growth of domesticated animals,improving effectivness of food utilization ba domesticated animals and improving leanness of domesticated animals and fodder pre-mixture
EP0128120A3 (de) 1983-06-02 1985-11-13 Ciba-Geigy Ag Trisubstituierte Oxazolidinone
ES8502099A1 (es) 1983-08-02 1984-12-16 Espanola Farma Therapeut Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina.
CA1249992A (en) 1983-11-10 1989-02-14 Marcel Muller Oxazolidines
GB2151612B (en) 1983-11-25 1988-08-03 Lafon Labor The use of the family of 2-amino-1-(methoxyphenyl)-1- ethanol derivatives for the manufacture of a medicament for use as a vasodilating agent
US4614746A (en) 1985-03-21 1986-09-30 American Cyanamid Company 5-fluorobenzonitrile derivatives for increasing the lean meat to fat ratio and/or enhancing the growth rate of warm-blooded animals
DE3514725A1 (de) 1985-04-24 1986-10-30 Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim Ss(pfeil abwaerts)2(pfeil abwaerts)-mimetica vom typ der 4-amino-phenylaethanolamine zur verhinderung von peptischen magen-geschwueren
US4863959A (en) 1985-10-17 1989-09-05 American Cyanamid Company Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals
ATE61794T1 (de) 1985-10-17 1991-04-15 American Cyanamid Co Anthranilonitrilderivate und verwandte verbindungen als nuetzliche stoffe zur wachstumsbeschleunigung, zur verbesserung der futterqualitaet und zur steigerung des fleisch/fett-verhaeltnisses bei warmbluetigen tieren.
DE3615293A1 (de) * 1986-05-06 1987-11-12 Bayer Ag Verwendung von heteroarylethylaminen zur leistungsfoerderung bei tieren, heteroarylethylamine und verfahren zu ihrer herstellung
GB8714901D0 (en) 1986-07-23 1987-07-29 Ici Plc Amide derivatives
US4814350A (en) 1986-09-10 1989-03-21 American Cyanamid Company Method of treating diabetes with 5-[1-hydroxy-2-(isopropylamino)ethyl]anthranilonitrile
IE60964B1 (en) 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
DK123788A (da) 1987-03-10 1988-09-11 Beecham Group Plc Morpholin-derivater
DE3725084A1 (de) * 1987-07-29 1989-02-09 Bayer Ag Substituierte pyridinethanolamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren
ATE116284T1 (de) 1987-08-12 1995-01-15 Sanofi Sa Verfahren zur o-alkylierung von n- (hydroxy)aralkylphenylethanolamin.
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
FR2647310B1 (fr) 1989-05-29 1992-01-17 Roussel Uclaf Utilisation de beta-adrenergiques pour la fabrication de compositions zootechniques
IE65511B1 (en) 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins
ES2085468T3 (es) 1990-01-05 1996-06-01 Sepracor Inc Albuterol r(-) opticamente puro para tratar el asma.
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5726165A (en) 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US6037362A (en) 1996-01-10 2000-03-14 Asahi Kasei Kogyo Kabushiki Kaisha Tricyclic compounds and drug compositions containing the same
WO1998022480A1 (en) 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
EP0968209A1 (en) 1997-01-28 2000-01-05 Merck & Co., Inc. THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
JP3193706B2 (ja) 1997-10-17 2001-07-30 山之内製薬株式会社 アミド誘導体又はその塩
AU2223899A (en) 1998-01-12 1999-07-26 Georgetown University Medical Center G protein-related kinase mutants in essential hypertension
AU2781899A (en) 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
CN1161018C (zh) 1998-06-18 2004-08-11 诺瓦提斯公司 防治害虫的组合物
ES2182543T3 (es) 1998-06-18 2003-03-01 Novartis Ag Composicion para ahuyentar parasitos.
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
CA2423792A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20100022658A1 (en) 2000-11-01 2010-01-28 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans
AU782148B2 (en) 2001-03-29 2005-07-07 Molecular Design International, Inc. Beta3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
CN1276911C (zh) 2001-09-30 2006-09-27 沈阳药科大学 具有β2-受体兴奋作用的新型苯乙醇胺类化合物及其制法
WO2003032969A2 (en) 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
JP2005533771A (ja) 2002-06-04 2005-11-10 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼiv阻害剤としてのフッ素化環式アミド
EP1540332A1 (en) 2002-07-03 2005-06-15 Duke University Methods of screening compounds for grk6 modulating activity
US6831081B2 (en) 2002-09-04 2004-12-14 Pharmacia & Upjohn 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
AU2003286776A1 (en) 2002-10-30 2004-06-07 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
WO2004085414A1 (en) 2003-03-26 2004-10-07 Pharmacia & Upjohn Company Llc Process to produce enantiomerically enriched 1-aryl- and 1-heteroaryl-2-aminoethanols
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
AU2003904237A0 (en) 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
CA2538415A1 (en) 2003-09-15 2005-03-24 Wilfred Wayne Lautt Use of antagonists of hepatic sympathetic nerve activity
JP2005097149A (ja) 2003-09-24 2005-04-14 Dainippon Pharmaceut Co Ltd [3−[(2r)−[[(2r)−(3−クロロフェニル)−2−ヒドロキシエチル]アミノ]プロピル]−1h−インドール−7−イルオキシ]酢酸の溶媒和物
FR2861073B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CA2554959A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
DE102004019539A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
WO2005114195A1 (en) 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 4 (grk4)
KR20070027747A (ko) 2004-06-30 2007-03-09 콤비네이토릭스, 인코포레이티드 대사 질환의 치료 방법 및 시약
BRPI0513262A (pt) 2004-07-12 2008-04-29 Bayer Cropscience Ag heterociclos substituìdos
EP1786410A2 (en) 2004-09-07 2007-05-23 Sosei R&D Ltd. The treatment of inflammatory disorders and pain
US20100173928A1 (en) 2005-01-28 2010-07-08 Sabatini David M Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex
ES2348920T3 (es) * 2005-04-13 2010-12-17 Astion Development A/S Agonistas de adrenoceptores beta-2 para el tratamiento de enfermedades del tejido conectivo de la piel.
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
CN101252952A (zh) 2005-08-29 2008-08-27 橘生药品工业株式会社 用于由泪液减少所引起的疾病的预防或治疗剂
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007217368A (ja) 2006-02-17 2007-08-30 Japan Health Science Foundation PGC−1α発現促進剤及びPGC−1α発現抑制剤、並びにそれらの使用方法
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
EP1991211A1 (en) 2006-02-28 2008-11-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
GB0604826D0 (en) 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
JP2009531334A (ja) 2006-03-24 2009-09-03 ナショナル リサーチ カウンセル オブ カナダ 抗糖尿病性白内障化合物及びそれらの用途
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
CA2660707C (en) 2006-08-10 2014-07-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
KR100821567B1 (ko) 2006-11-01 2008-04-15 한국화학연구원 광학 활성 2-설포닐옥시-1-페닐에탄올 유도체의 제조방법
GB0624757D0 (en) 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CA2638573C (en) 2008-04-30 2013-03-12 Universiteit Gent Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
US8389561B2 (en) 2008-04-30 2013-03-05 Universiteit Gent Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
FR2932818B1 (fr) 2008-06-23 2015-12-04 Centre Nat Rech Scient Lignee d'adipocytes bruns humains et procede de differenciation a partir d'une lignee de cellules hmads.
WO2010016939A1 (en) 2008-08-08 2010-02-11 The Trustees Of Columbia University In The City Of New York Hypoglycemic dihydropyridones
US8637524B2 (en) 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
US20110055367A1 (en) 2009-08-28 2011-03-03 Dollar James E Serial port forwarding over secure shell for secure remote management of networked devices
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
AU2011224241B2 (en) 2010-03-10 2014-05-08 Sri International The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
JP2013522302A (ja) 2010-03-14 2013-06-13 グローブイミューン,インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
EP2426202A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kinases as targets for anti-diabetic therapy
US20120122843A1 (en) * 2010-11-11 2012-05-17 Astrazeneca Ab Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
US9657348B2 (en) 2013-01-13 2017-05-23 Atrogi Ab Method of screening compounds for the treatment of diabetes
CN103565784A (zh) 2013-11-04 2014-02-12 匡仲平 一种减肥药剂
US9891212B2 (en) 2013-12-16 2018-02-13 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
TWI659019B (zh) * 2014-02-28 2019-05-11 日商帝人製藥股份有限公司 吡唑醯胺衍生物
WO2016004995A1 (en) 2014-07-09 2016-01-14 Atrogi Ab A method of screening for a compound capable of stimulating glucose transport into brown and/or brite adipocytes of a mammal, a kit for use in such a method
CN105078946A (zh) 2015-08-07 2015-11-25 重庆理工大学 沙美特罗在治疗二型糖尿病、胰岛素抵抗药物上的应用
WO2017153737A1 (en) * 2016-03-07 2017-09-14 Atrogi Ab Compounds for the treatment of hyperglycaemia
CN106083837B (zh) 2016-05-27 2018-08-31 浙江普洛得邦制药有限公司 一种噁唑烷酮类抗菌药物及其中间体的制备方法
GB201612165D0 (en) 2016-07-13 2016-08-24 Atrogi Ab Combinations for the treatment of type 2 diabetes
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903827D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
JP2022527769A (ja) 2019-03-27 2022-06-06 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
CA3144093A1 (en) 2019-07-01 2021-01-07 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
GB202015044D0 (en) 2020-09-23 2020-11-04 Atrogi Ab New compounds and methods
GB202015035D0 (en) 2020-09-23 2020-11-04 Atrogi Ab New compounds and methods

Also Published As

Publication number Publication date
JP7358338B2 (ja) 2023-10-10
HUE057426T2 (hu) 2022-05-28
US20220133703A1 (en) 2022-05-05
RU2020108523A (ru) 2021-10-15
AU2018332501A1 (en) 2020-04-23
JP2023182659A (ja) 2023-12-26
RU2020108523A3 (pl) 2022-03-23
US20210030731A1 (en) 2021-02-04
SI3681872T1 (sl) 2022-04-29
KR20230175328A (ko) 2023-12-29
MX2020002825A (es) 2020-09-14
US12036210B2 (en) 2024-07-16
AU2018332501B2 (en) 2023-09-21
ES2902073T3 (es) 2022-03-24
EP3681872A1 (en) 2020-07-22
CA3075707A1 (en) 2019-03-21
EP3681872B1 (en) 2021-11-17
IL273180A (en) 2020-04-30
HRP20220177T1 (hr) 2022-04-29
EP3971168A1 (en) 2022-03-23
CN111315726A (zh) 2020-06-19
LT3681872T (lt) 2022-01-25
US11357757B2 (en) 2022-06-14
CY1125004T1 (el) 2023-01-05
RS62895B1 (sr) 2022-03-31
BR112020005113A2 (pt) 2020-09-15
PT3681872T (pt) 2021-12-22
JP2020534263A (ja) 2020-11-26
WO2019053427A1 (en) 2019-03-21
PL3681872T3 (pl) 2022-04-04
GB201714745D0 (en) 2017-10-25
MX2023011675A (es) 2023-10-18

Similar Documents

Publication Publication Date Title
KR20200052936A (ko) 과혈당증의 치료에 사용하기 위한 헤테로아릴 치환된 베타-히드록시에틸아민
KR20200051777A (ko) 플루오로페닐 베타-히드록시에틸아민 및 과혈당증의 치료에서의 이의 용도
KR20200051776A (ko) 베타-히드록시 헤테로사이클릭 아민 및 과혈당증의 치료에서의 이의 용도
KR20210141622A (ko) 과혈당증의 치료에 유용한 헤테로시클릴(페닐)메탄올 화합물
KR20220002903A (ko) 과혈당증의 치료에 유용한 헤테로아릴(헤테로시클릴)메탄올 화합물
JP2019510082A (ja) 高血糖症の治療のための化合物
KR20200052937A (ko) 카이랄 베타-히드록시에틸아민 및 과혈당증의 치료에서의 이의 용도
RU2801096C2 (ru) Фторфенил-бета-гидроксиэтиламины и их применение для лечения гипергликемии
WO2024200777A1 (en) Substituted hydroxymethyl pyrrolidines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
E902 Notification of reason for refusal
E902 Notification of reason for refusal